Merck Jumps 5% on EU Approval for Keytruda-Padcev Bladder Cancer Combo
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
mrkmerck
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Merck & Co. shares surged on June 24, 2026, after the pharmaceutical giant secured European Union approval for the combination of its blockbuster drug Keytruda with Seagen's Padcev to treat advanced bladder cancer. The regulatory greenlight, reported by SeekingAlpha, triggered a significant rally in Merck's stock. MRK shares traded at $119.60, up 5.03% on the day, with an intraday high of $119.80. This move solidifies Merck's dominance in the lucrative immuno-oncology market and extends the commercial runway for Keytruda ahead of anticipated patent expiries later this decade.
The approval arrives at a critical juncture for Merck, with Keytruda's foundational patents in the United States beginning to expire in 2028. The drug generated over $25 billion in annual revenue, making market expansion through new indications and combinations a primary strategic objective. The EU decision for previously untreated advanced urothelial cancer follows a similar approval by the U.S. Food and Drug Administration in late 2025, based on Phase 3 trial data showing the combination significantly improved overall survival compared to standard chemotherapy.
This regulatory success also underscores the strategic value of Merck's collaboration with Seagen, a Pfizer company, which was acquired for its targeted oncology portfolio. The macro backdrop for large-cap pharmaceuticals remains favorable, with the sector attracting defensive flows amid broader market volatility tied to interest rate uncertainty. The approval directly addresses investor concerns about Merck's growth prospects in a post-Keytruda exclusivity world, providing a tangible pathway for sustained revenue.
The market reaction was immediate and pronounced, with Merck's stock advancing from its opening range near $117.00 to a session high of $119.80. The 5.03% single-day gain significantly outperforms the S&P 500 Healthcare Sector's average daily movement of approximately 0.7% year-to-date. Trading volume for MRK was more than double its 30-day average, indicating strong institutional conviction behind the move.
The financial implications are substantial. The bladder cancer market in Europe represents a multi-billion dollar opportunity. Analysts at Jefferies previously estimated that this specific combination therapy could achieve peak global sales exceeding $3 billion, with European sales contributing a significant portion. The news propelled Merck's market capitalization increase by over $10 billion during the session.
| Metric | Pre-Announcement (Prev. Close) | Post-Announcement (Intraday High) | Change |
|---|---|---|---|
| MRK Share Price | $113.87 | $119.80 | +5.21% |
| Market Cap | ~$288 Billion | ~$303 Billion | +~$15 Billion |
The approval strengthens Keytruda's competitive moat against rival immuno-oncology drugs from Bristol-Myers Squibb and Roche.
The primary beneficiary is Merck, as the approval directly defends its largest revenue stream. Second-order gains extend to Pfizer, which now owns Seagen and receives royalties and collaboration revenue from Padcev sales. PFE shares saw a modest uptick in sympathy. Companies with competing bladder cancer treatments, such as AstraZeneca, may face increased competitive pressure, potentially dampening investor sentiment around their oncology pipelines.
A key risk acknowledged by analysts is the high cost of combination therapies and the potential for pushback from European cost-effectiveness bodies, which could limit pricing and market access. The long-term commercial success will depend on reimbursement decisions across individual EU member states. Positioning data from options markets showed a surge in bullish call buying on MRK, with heavy volume in short-dated contracts, indicating traders are betting on continued momentum.
Flow trends suggest institutional investors are rotating into large-cap, high-quality pharma names with visible earnings growth, a theme Merck now embodies more strongly. The sector ETF, XLV, also saw net inflows, though more muted than Merck's standout performance.
The immediate catalyst is Merck's second-quarter earnings report, scheduled for late July 2026, where management will provide updated revenue guidance incorporating the EU approval. Investors will scrutinize the initial launch trajectory in key European markets like Germany, France, and the UK.
Key levels to watch for MRK include the psychological resistance at $120.00, a break of which could target the 52-week high near $125. A reversal below the day's low of $117.00 would signal a failure of the bullish breakout. The next major regulatory milestone is a potential approval decision for this combination in Japan, expected in the fourth quarter of 2026.
Market participants should also monitor commentary from the European Medicines Agency regarding any label expansions for the combo into adjacent cancer types, which would represent further upside. The performance of Pfizer's stock will serve as a barometer for the partnership's perceived success.
The EU approval is a significant long-term positive as it helps delay the revenue cliff faced when Keytruda's patents expire. By expanding the drug's use into new treatment settings with a potent combination, Merck can increase the average revenue per patient and solidify physician loyalty. This defensive maneuver is critical for maintaining earnings stability beyond 2028 and supports a higher valuation multiple for the stock.
The Keytruda-Padcev combination demonstrated a superior overall survival benefit compared to traditional platinum-based chemotherapy in clinical trials. This represents a shift in the standard of care for eligible patients. Padcev is an antibody-drug conjugate that precisely targets cancer cells, and its overlap with Keytruda's mechanism of unlocking the immune system creates a powerful two-pronged attack on the tumor.
Besides Merck and Pfizer, several other biopharma firms are active in this space. AstraZeneca is developing combinations involving its Imfinzi immunotherapy. Gilead Sciences, through its acquisition of Immunomedics, has an antibody-drug conjugate, Trodelvy, being explored in urothelial cancer. Bristol-Myers Squibb's Opdivo is also approved in later-line settings, making it a competitive landscape.
Merck's EU approval fortifies its core franchise against looming patent expires, justifying the stock's sharp re-rating.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.